题目内容

In 1983, a group of scientists from Baylor College of Medicine in Houston, Texas, proposed that gene therapy could one day be a viable approach for treating Lesch-Nyhan disease, a rare ___________________.

A. blood disorder
B. neurological disorder
C. bone disorder
D. joint disorder

查看答案

搜索结果不匹配？点我反馈

更多问题

In ______, Glybera (alipogene tiparvovec) became the first approved viral gene-therapy treatment for familial lipoprotein lipase deficiency (LPLD) in Europe.

A. 2006
B. 2010
C. 2012
D. 2015

查看答案

The marketing authorization for Glybera clearly represents a milestone in the development of gene therapy as an accessible therapeutic option for familial lipoprotein lipase deficiency (LPLD) patients. Glybera is a recombinant __________ for direct intramuscular injection.

A. adenovirus
B. AAV
C. HPV
D. retrovirus

查看答案

In March 2017, Yescarta (axicabtagene ciloleucel), a ________-directed genetically modified autologous T cell immunotherapy, was approved by FDA.

A. CD15
B. CD19
CD29
D. CD44

查看答案

On August 30, 2017, the US FDA approved Kymriah (tisagenlecleucel, Novartis)for the treatment of patients aged ≤25 years with B-cell precursor ______________________ that is refractory, in second relapse, or later relapse.

A. acute myelogenous (or myeloid) leukemia (AML)
B. acute lymphocytic (or lymphoblastic) leukemia (ALL)
C. chronic myelogenous (or myeloid) leukemia (CML)
D. chronic lymphocytic (or lymphoblastic) leukemia (CLL)

查看答案

In 1983, a group of scientists from Baylor College of Medicine in Houston, Texas, proposed that gene therapy could one day be a viable approach for treating Lesch-Nyhan disease, a rare ___________________.

A. blood disorder B. neurological disorder C. bone disorder D. joint disorder

In ______, Glybera (alipogene tiparvovec) became the first approved viral gene-therapy treatment for familial lipoprotein lipase deficiency (LPLD) in Europe.

The marketing authorization for Glybera clearly represents a milestone in the development of gene therapy as an accessible therapeutic option for familial lipoprotein lipase deficiency (LPLD) patients. Glybera is a recombinant __________ for direct intramuscular injection.

In March 2017, Yescarta (axicabtagene ciloleucel), a ________-directed genetically modified autologous T cell immunotherapy, was approved by FDA.

On August 30, 2017, the US FDA approved Kymriah (tisagenlecleucel, Novartis)for the treatment of patients aged ≤25 years with B-cell precursor ______________________ that is refractory, in second relapse, or later relapse.

A. blood disorder
B. neurological disorder
C. bone disorder
D. joint disorder